Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NEO
HOLDNeoGenomics, Inc. · Healthcare · United States · $1.8B · Avg Vol: $50M/d
COMPANY DESCRIPTION
NeoGenomics, Inc. is a leading oncology-focused diagnostics company, providing comprehensive cancer testing and information services to pathologists, oncologists, hospitals, and pharmaceutical companies. The company benefits from a broad portfolio of advanced oncology diagnostic tests, coupled with specialized expertise and a nationwide presence. NeoGenomics is a prominent player in precision oncology, offering critical diagnostic and prognostic insights that guide treatment decisions and support drug development.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 509.7M | 591.6M | 660.6M | 727.3M | 12.6% | 746.0M | 800.4M | 880.7M | 10.0% |
| EPS | -1.16 | -0.70 | -0.62 | -0.84 | — | -0.75 | — | — | — |
| Shares | 126.9M | 127.4M | 128.1M | 129.0M | +1.6% | 130.2M | — | — | — |
| Debt | 610.9M | 611.7M | 605.3M | 409.5M | -12.5% | 408.5M | — | — | — |
| Equity | 998.0M | 941.5M | 902.3M | 836.6M | -5.7% | — | — | — | — |
| Op CF | -66.0M | -2.0M | 7.0M | 5.2M | -25.5% | 22.4M | — | — | — |
| Inv CF | 0.5M | 76.7M | 12.9M | -12.3M | — | — | — | — | — |
| Fin CF | 11.8M | 4.6M | 4.6M | -200.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NEO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NEO | NeoGenomics, Inc.(you) | $1.8B | 48 | HOLD |
| ADPT | Adaptive Biotechnologies Corporation | $3.6B | 43 | HOLD |
| TWST | Twist Bioscience Corporation | $5.6B | 45 | HOLD |
| OPK | OPKO Health, Inc. | $921M | 34 | SELL |
| BLLN | BillionToOne, Inc. | $5.8B | 41 | HOLD |
| CDNA | CareDx, Inc. | $1.9B | 78 | BUY |
| PSNL | Personalis, Inc. | $1.3B | 22 | SELL |
| WGS | GeneDx Holdings Corp. | $1.8B | 14 | STRONG SELL |
| RDNT | RadNet, Inc. | $4.8B | 31 | SELL |
| GRAL | GRAIL, Inc. | $2.9B | 21 | SELL |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.7%